Forward-looking price predictions for Perspective Therapeutics (CATX) reflect the speculative nature of early-stage biopharmaceutical research firms. Algorithmic forecasts and institutional models project values based on clinical trial milestones, capital requirements, and broader healthcare sector liquidity trends rather than traditional cash flow multiples.